[go: up one dir, main page]

ES2216055T3 - Metodos para reducir o mantener niveles reducidos de lipidos en sangre usando composiciones de proteina ob. - Google Patents

Metodos para reducir o mantener niveles reducidos de lipidos en sangre usando composiciones de proteina ob.

Info

Publication number
ES2216055T3
ES2216055T3 ES96926873T ES96926873T ES2216055T3 ES 2216055 T3 ES2216055 T3 ES 2216055T3 ES 96926873 T ES96926873 T ES 96926873T ES 96926873 T ES96926873 T ES 96926873T ES 2216055 T3 ES2216055 T3 ES 2216055T3
Authority
ES
Spain
Prior art keywords
methods
lipids
blood
reduce
reduced levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96926873T
Other languages
English (en)
Inventor
Mary Ann Pelleymounter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ES2216055T3 publication Critical patent/ES2216055T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE PROPORCIONAN METODOS Y COMPOSICIONES RELACIONADAS CON EL USO DE LAS PROTEINAS OB PARA EL TRATAMIENTO DE ESTADOS RELACIONADOS CON LOS NIVELES DE LIPIDOS SANGUINEOS. ESTOS METODOS Y COMPOSICIONES INCLUYEN LOS QUE SON UTILES PARA EL TRATAMIENTO DE COLESTEROL ELEVADO, NIVELES DE TRIGLICERIDOS ELEVADOS, PLACA ARTERIAL, HIPERTENSION, Y PREVENCION DE FORMACION DE PIEDRAS DE LA VESICULA BILIAR.
ES96926873T 1995-08-17 1996-08-02 Metodos para reducir o mantener niveles reducidos de lipidos en sangre usando composiciones de proteina ob. Expired - Lifetime ES2216055T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51626395A 1995-08-17 1995-08-17

Publications (1)

Publication Number Publication Date
ES2216055T3 true ES2216055T3 (es) 2004-10-16

Family

ID=24054813

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96926873T Expired - Lifetime ES2216055T3 (es) 1995-08-17 1996-08-02 Metodos para reducir o mantener niveles reducidos de lipidos en sangre usando composiciones de proteina ob.

Country Status (13)

Country Link
US (1) US20020147142A1 (es)
EP (1) EP0865294B1 (es)
JP (1) JP4173913B2 (es)
AT (1) ATE259650T1 (es)
AU (1) AU6688896A (es)
CA (1) CA2229450A1 (es)
DE (1) DE69631605T2 (es)
DK (1) DK0865294T3 (es)
ES (1) ES2216055T3 (es)
MX (1) MX9801159A (es)
PT (1) PT865294E (es)
WO (1) WO1997006816A1 (es)
ZA (1) ZA966798B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
EP0833835A4 (en) * 1995-06-22 1999-05-26 Lilly Co Eli OBESITY PROTEIN INTERMEDIATE PRODUCTS, THEIR PRODUCTION AND USE
US5830450A (en) * 1996-06-19 1998-11-03 Lallone; Roger L. Compositions of leptin bound to an apolipoprotein
US7332338B2 (en) 1996-10-04 2008-02-19 Lexicon Pharmaceuticals, Inc. Vectors for making genomic modifications
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US6436707B1 (en) 1998-03-27 2002-08-20 Lexicon Genetics Incorporated Vectors for gene mutagenesis and gene discovery
US6808921B1 (en) 1998-03-27 2004-10-26 Lexicon Genetics Incorporated Vectors for gene mutagenesis and gene discovery
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
AU5347099A (en) * 1998-08-10 2000-03-06 Amgen, Inc. Dextran-leptin conjugates, pharmaceutical compositions and related methods
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
CA2388417A1 (en) 1999-09-22 2001-03-29 Genset Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
DK2219031T3 (da) 2001-10-22 2013-06-17 Amgen Inc Anvendelse af leptin til behandling af human lipoatrofi og fremgangsmåde til bestemmelse af prædisposition for behandlinngen
JP3813152B2 (ja) 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
EP1462116A1 (en) * 2003-03-29 2004-09-29 Villitech SARL Composition for treating the gastrointestinal tract
GB0307367D0 (en) * 2003-03-29 2003-05-07 Twg Composition and method for treating the gastro-intestinal tract
US20060003008A1 (en) 2003-12-30 2006-01-05 Gibson John W Polymeric devices for controlled release of active agents
US20090156474A1 (en) 2004-11-01 2009-06-18 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
US7629315B2 (en) * 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
CA3138758A1 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Highly soluble leptins
HUE040496T2 (hu) 2012-09-27 2019-03-28 Childrens Medical Ct Corp Vegyületek elhízás kezelésére és alkalmazási eljárásaik
LT3074033T (lt) 2013-11-26 2019-02-25 The Children`S Medical Center Corporation Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
FI3509624T3 (fi) 2016-09-12 2023-10-18 Amryt Pharmaceuticals Inc Menetelmiä neutraloivien anti-leptiini -vasta-aineiden havaitsemiseksi

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof

Also Published As

Publication number Publication date
MX9801159A (es) 1998-05-31
WO1997006816A1 (en) 1997-02-27
ZA966798B (en) 1997-02-19
DK0865294T3 (da) 2004-06-28
JPH11511165A (ja) 1999-09-28
PT865294E (pt) 2004-07-30
EP0865294B1 (en) 2004-02-18
US20020147142A1 (en) 2002-10-10
DE69631605T2 (de) 2005-01-05
EP0865294A1 (en) 1998-09-23
AU6688896A (en) 1997-03-12
CA2229450A1 (en) 1997-02-27
DE69631605D1 (de) 2004-03-25
JP4173913B2 (ja) 2008-10-29
ATE259650T1 (de) 2004-03-15

Similar Documents

Publication Publication Date Title
ES2216055T3 (es) Metodos para reducir o mantener niveles reducidos de lipidos en sangre usando composiciones de proteina ob.
ATE202706T1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
DE69627690D1 (de) Liposomale formulierungen von mitoxantron
WO2002060955A3 (en) Modified antibodies and methods of use
CY1112927T1 (el) Αντισωματα κατα της ανθρωπινης il-12
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
WO2000047618A3 (en) HUMAN β-SECRETASE ENZYME, INHIBITORS AND THEIR COMPOSITIONS AND USES
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
DE69822496D1 (de) Lipidkomplex-lyophilisat von wasserunlöslichen porphyrinen
ATE116848T1 (de) Verwendung von baclofen zur herstellung von arzneimitteln zur behandlung von angina pectoris.
DK0858504T3 (da) Diagnostiske midler mod og behandlinger af periodontale sygdomme
EP0785772A4 (en) LYOPHILISATE OF A LIPID COMPLEX OF WATER-INSOLUBLE CAMTOTHECINS
ATE82127T1 (de) N-acetylglucosamin-zubereitungen zur buccalen anwendung.
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
NO20001799L (no) FremgangsmÕte for rensing av kirurgiske instrumenter
NO961423D0 (no) Oligopeptider avledet fra C-reaktive proteinfragmenter
DE69829995D1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
ATE211650T1 (de) Verwendung von topische präparationen mit glyceryl trinitrat und lanolin zur behandlung von erektilen funktionsstörungen
EA200401295A1 (ru) Статиновая терапия для усиления поддержания когнитивной функции
DE69821227D1 (de) Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin